Drugs / Rexlemestrocel-L
Rexlemestrocel-L
also known as
Stem Cells · stromal vascular fraction · Adipose-derived stem cells · SVF · HuCNS-SC · NeoFuse · Allo-hMSCs · ADSCs · +23 more
Trials 73 · started per year
today
1
1
1
1
2
6
3
5
5
7
8
3
9
3
3
3
3
3
2
3
1
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT04771442 | Sep 2022 → Dec 2023 | Peyronie disease | Esbjerg Hospital - University Hospital of Southern Denmark | Completed | No outcome recorded |
| Phase 1 | NCT05232903 | Mar 2022 → Jun 2024 | intracerebral hemorrhage | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05354544 | Aug 2021 → Dec 2024 | — | Shane A. Shapiro | Terminated | No outcome recorded |
| Phase 1 | NCT03058068 | Dec 2020 → Sep 2027 | cystic fibrosis | Joshua M Hare | Withdrawn | No outcome recorded |
| Phase 1 | NCT02677350 | Dec 2019 → Dec 2025 | perianal Crohn disease | Joshua M Hare | Withdrawn | No outcome recorded |
| Phase 1 | NCT03940950 | Jul 2019 → May 2025 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02675556 | Oct 2017 → Mar 2019 | — | Joshua M Hare | Terminated | No outcome recorded |
| Phase 1 | NCT03282760 | Sep 2017 → May 2021 | secondary progressive multiple sclerosis | Casa Sollievo della Sofferenza IRCCS | Completed | No outcome recorded |
| Phase 1 | NCT03882983 | Sep 2017 → Dec 2022 | chronic ulcer of skin | Antria | Unknown | No outcome recorded |
| Phase 1 | NCT03295292 | Aug 2017 → Dec 2019 | corneal disorder | L.V. Prasad Eye Institute | Unknown | No outcome recorded |
| Phase 1 | NCT02398604 | Apr 2015 → Mar 2019 | hypoplastic left heart syndrome | Longeveron Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01625351 | Aug 2012 → Feb 2020 | Ewing sarcoma, Wilms tumor, clear cell adenocarcinoma, germ cell tumor +7 | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01640067 | Dec 2011 → Dec 2015 | amyotrophic lateral sclerosis | Azienda Ospedaliera Santa Maria, Terni, Italy | Completed | No outcome recorded |
| Phase 1 | NCT01238315 | Nov 2010 → Apr 2011 | neuronal ceroid lipofuscinosis | StemCells, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT01626625 | Apr 2010 → Apr 2015 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT01005004 | Nov 2009 → Oct 2012 | Pelizaeus-Merzbacher disease, connatal form | StemCells, Inc. | Completed | No outcome recorded |
| Phase 1/227 trials | ||||||
| Phase 1/2 | NCT05305833 | Oct 2021 → Dec 2022 | osteoarthritis, temporomandibular joint disorder | TC Erciyes University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04050163 | Jan 2021 → May 2023 | myocardial infarction | Honya Medical Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT03487731 | Dec 2020 → Dec 2025 | — | Joshua M Hare | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03061110 | Nov 2018 → Dec 2020 | radiation-induced disorder | Midwestern Regional Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03079401 | Nov 2017 → Dec 2022 | atrioventricular septal defect, hypoplastic left heart syndrome | Boston Children's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03189628 | Mar → Aug 2017 | — | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03067857 | Sep 2016 → Jan 2019 | lateral sclerosis, progressive bulbar palsy, progressive muscular atrophy | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02688049 | Jan 2016 → Dec 2021 | spinal cord injury | Chinese Academy of Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02520843 | Oct 2015 → Feb 2018 | Crohn disease | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 1/2 | NCT02645305 | Jun 2015 → Sep 2016 | chronic obstructive pulmonary disease | University of Science Ho Chi Minh City | Unknown | No outcome recorded |
| Phase 1/2 | NCT02546882 | Feb 2015 → Jun 2016 | — | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03069209 | Jan 2015 → Jun 2021 | primary ovarian failure | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02846675 | Nov 2014 → Jul 2017 | osteoarthritis | Shanghai East Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02000362 | Aug 2014 → Sep 2018 | Crohn disease | Kang Stem Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02041910 | Jan 2014 → Jan 2015 | azoospermia | Hesham Saeed Elshaer | Unknown | No outcome recorded |
| Phase 1/2 | NCT02043743 | Jan → Apr 2014 | primary ovarian failure | El-Rayadh Fertility Centre | Unknown | No outcome recorded |
| Phase 1/2 | NCT01843387 | Jul 2013 → Sep 2014 | diabetic kidney disease, type 2 diabetes mellitus | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01860417 | Jun 2013 → Dec 2015 | intervertebral disk degenerative disorder | Red de Terapia Celular | Completed | No outcome recorded |
| Phase 1/2 | NCT02638714 | Apr 2013 → Sep 2021 | optic nerve disorder | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02025270 | Oct 2012 → Oct 2016 | male infertility | Al-Azhar University | Completed | No outcome recorded |
| Phase 1/2 | NCT01576328 | Apr 2012 → Oct 2013 | type 2 diabetes mellitus | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01584713 | Dec 2011 → Jul 2012 | intestinal fistula | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 1/2 | NCT01321333 | Mar 2011 → Apr 2015 | spinal cord injury | StemCells, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01106417 | Jun 2010 → May 2012 | cervical disk degenerative disorder, spinal stenosis, spondylolisthesis | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01087996 | Mar 2010 → Apr 2011 | disease related to hematopoietic stem cell transplant | University of Miami | Completed | No outcome recorded |
| Phase 1/2 | NCT00810212 | Nov 2008 → Nov 2011 | intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis | Mesoblast, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00549913 | Oct 2007 → Aug 2013 | intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT07134712 | Mar 2026 → Dec 2027 expected | acute myocardial infarction | Honya Medical Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03673748 | Dec 2022 → Dec 2026 expected | lupus erythematosus, lupus nephritis | Red de Terapia Celular | Recruiting | No outcome recorded |
| Phase 2 | NCT04050111 | Aug 2019 → Feb 2021 | osteoarthritis, knee | Swiss Medica XXI Century S.A. | Unknown | No outcome recorded |
| Phase 2 | NCT03308006 | Jan → Dec 2018 | osteoarthritis, knee | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 2 | NCT02865421 | Jun → Aug 2017 | androgenetic alopecia | King Edward Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02866552 | Jan 2017 → Jan 2019 | systemic sclerosis | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 2 | NCT02526576 | Aug 2015 → Jul 2017 | facial hemiatrophy | Antria | Completed | No outcome recorded |
| Phase 2 | NCT02467634 | Jun 2015 → May 2016 | age-related macular degeneration | StemCells, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02163876 | Oct 2014 → May 2016 | spinal cord injury | StemCells, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02092870 | Sep 2013 → Sep 2015 | decubitus ulcer, ulcer of lower limbs | Tower Outpatient Surgical Center | Completed | No outcome recorded |
| Phase 2 | NCT01621477 | Aug 2012 → Dec 2015 | acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1 | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01586715 | Mar 2012 → May 2013 | anal fistula | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 2 | NCT01097486 | Jun 2010 → Jul 2013 | cervical disk degenerative disorder, spinal stenosis, spondylolisthesis | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00996073 | Sep 2009 → Jul 2012 | intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00683046 | Nov 2001 → Dec 2014 | Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2 | University of Chicago | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06325566 | Jul 2024 → Jul 2027 expected | intervertebral disk degenerative disorder | Mesoblast, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02412735 | Mar 2015 → May 2020 | intervertebral disk degenerative disorder | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02672267 | Jul 2014 → Apr 2016 | myocardial infarction | Altaco XXI, LLP | Completed | No outcome recorded |
| Phase 3 | NCT02032004 | Mar 2014 → Jan 2020 | heart failure | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07405840 | Jun 2025 → Aug 2026 overdue | osteoarthritis | Clinical Center of Vojvodina | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03388840 | Jan 2018 → Jan 2021 | androgenetic alopecia | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02871466 | Jan 2010 → Jan 2022 | congestive heart failure | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07114692 | Sep 2025 → Sep 2027 expected | — | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| — | NCT07094958 | Jul → Dec 2025 overdue | acne | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06524011 | Dec 2024 → Dec 2025 overdue | — | Zagazig University | Not yet recruiting | No outcome recorded |
| — | NCT04393415 | May → Aug 2020 | viral infectious disease | Aljazeera Hospital | Unknown | No outcome recorded |
| — | NCT02923219 | Jan 2017 → Jan 2020 | — | Xuzhou Medical University | Unknown | No outcome recorded |
| — | NCT02975960 | Oct 2016 → Oct 2017 | systemic sclerosis | The Catholic University of Korea | Completed | No outcome recorded |
| — | NCT02024269 | Dec 2013 → Dec 2016 | dry age related macular degeneration | Bioheart, Inc. | Withdrawn | No outcome recorded |
| — | NCT01702961 | Jun 2002 → Aug 2014 | Hodgkins lymphoma | Baylor College of Medicine | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02756884 Comparator | Jun 2015 → Jan 2019 | peripheral arterial disease | Arkansas Heart Hospital | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02558543 Comparator | Sep 2015 → Dec 2018 | systemic sclerosis | Assistance Publique Hopitaux De Marseille | Terminated | No outcome recorded |
| Phase 2 | NCT01851070 Comparator | Jul 2013 → May 2016 | rheumatoid arthritis | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01602328 Comparator | Jun 2012 → Jun 2014 | acute kidney injury | AlloCure Inc. | Terminated | No outcome recorded |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 82 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rexlemestrocel-L | “The study was a dose-escalating randomized placebo-controlled trial assessing one intravenous (IV) infusion of MPCs (rexlemestrocel-L; Mesoblast Inc.) 0.3 × 10(6)/kg (n = 15),...” PMID 26153271 ↗ Jul 20155“single intravenous (IV) infusion of allogeneic MPC (United States adopted name: rexlemestrocel-L) 150×106 (n=10), 300×106 (n=10) or placebo (n=10)” PMID 27743903 ↗ Sep 2016 |
| Known as | AC607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602328 ↗ |
| Known as | adipose tissue-derived stromal vascular fraction | “adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis” PMID 34297066 ↗ May 2022 |
| Known as | Adipose-derived stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01586715 ↗ |
| Known as | adipose-derived stromal vascular fraction | “Autologous adipose-derived stromal vascular fraction (ADSVF) is an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties.” PMID 29321063 ↗ Jan 2018 |
| Known as | ADSCs | “One group will receive Adipose Derived Stem Cells (ADSCs) alone and the other group will receive low frequency ultrasound before the addition of ADSCs.” NCT02756884 ↗1“features of adipose- derived stem cells (ADSCs).” PMID 32269011 ↗ Nov 2019 |
| Known as | ADSVF | “Autologous adipose-derived stromal vascular fraction (ADSVF) is an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties.” PMID 29321063 ↗ Jan 2018 |
| Known as | Allo-hMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03058068 ↗ |
| Known as | Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02677350 ↗ |
| Known as | Allogeneic human mesenchymal stem cells | “Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs)” NCT01087996 ↗ |
| Known as | Allogeneic Human Mesenchymal Stem Cells (hMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03487731 ↗ |
| Known as | Allogeneic Mesenchymal Precursor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01851070 ↗ |
| Known as | Allogenic Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01860417 ↗ |
| Known as | Autologous Stem Cells | “autologous e-ASC (Autologous Stem Cells)” NCT01586715 ↗ |
| Known as | autologous SVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02846675 ↗ |
| Known as | e-ASC | “autologous e-ASC (Autologous Stem Cells)” NCT01586715 ↗ |
| Known as | FURESTEM-CD Inj. | “Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)” NCT02000362 ↗ |
| Known as | hNSCs | “We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and...” PMID 25889343 ↗ Jan 20151“Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions).” NCT03282760 ↗ |
| Known as | HuCNS-SC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01005004 ↗ |
| Known as | Human Neural Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640067 ↗ |
| Known as | Mesenchymal stem cells (MSC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673748 ↗ |
| Known as | MiSaver | “MiSaver, a cellular therapy product” NCT07134712 ↗ |
| Known as | MPC | “single intravenous (IV) infusion of allogeneic MPC (United States adopted name: rexlemestrocel-L) 150×106 (n=10), 300×106 (n=10) or placebo (n=10)” PMID 27743903 ↗ Sep 2016 |
| Known as | MPCs | “Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.” NCT01851070 ↗ |
| Known as | NeoFuse | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01097486 ↗ |
| Known as | neural stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02688049 ↗ |
| Known as | Revascor | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545318 ↗ |
| Known as | Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05305833 ↗ |
| Known as | stromal vascular fraction | “Stromal vascular fraction (SVF) is a structural framework in the body's fat tissue, comprising mesenchymal stem cells, white blood cells, red blood cells, endothelial cells, T...” NCT05232903 ↗17“The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.” NCT05354544 ↗ “Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft” NCT03882983 ↗ “The stromal vascular fraction obtained from adipose tissue will be added to the graft” NCT02526576 ↗ |
| Known as | Stromal Vasular Fraction | “Biological: Stromal Vasular Fraction” NCT02526576 ↗ |
| Known as | SVF | “Stromal vascular fraction (SVF) is a structural framework in the body's fat tissue, comprising mesenchymal stem cells, white blood cells, red blood cells, endothelial cells, T...” NCT05232903 ↗7“Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars.” NCT07094958 ↗ “The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.” NCT05354544 ↗ “stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection” NCT02520843 ↗ “Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone” NCT06524011 ↗ “Autologous Adipose-Derived SVF (Stromal Vascular Fraction)” NCT03940950 ↗ “The harvested pellet is stromal vascular fraction (SVF)” NCT03189628 ↗ “to acquire the stromal vascular fraction (SVF).” NCT07114692 ↗ |
| Known as | Umbilical Cord Blood Derived Nucleated Cells | “MiSaver (Umbilical Cord Blood Derived Nucleated Cells)” NCT07134712 ↗ |
| Action | Activate | “enhance and activate the spermatogonial stem cells” NCT02025270 ↗ |
| Modality | Cell therapy | “immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse)” NCT00549913 ↗ |
| Route | Other | “intracerebral transplantation” NCT01005004 ↗ |